Reforming AI drug discovery: systemic data sharing, equitable incentives, and inclusive knowledge
Original framing: “Closing the data loop in AI-driven drug discovery” — MIT Technology Review
Robust scientific methodology demands transparent model validation, reproducibility, and external benchmarking against established assay data. Recent meta‑analyses show AI predictions often overfit to proprietary datasets, inflating perceived success rates. Embedding FAIR (Findable, Accessible, Interoperable, Reusable) standards and independent peer review can align AI outputs with rigorous drug discovery science.
AI‑driven drug discovery cannot deliver on its promise without dismantling the proprietary data silos and market‑centric incentives that have driven costs skyward for decades.
By weaving Indigenous pharmacological wisdom, historical lessons from open‑source initiatives, and cross‑cultural validation into a globally governed data commons, the field can generate more diverse, reproducible insights. Transparent regulatory sandboxes and reformed patent regimes will align commercial motivations with public health goals, while marginalised patient voices shape target priorities. Together, these systemic interventions create a feedback loop where scientific rigor, cultural inclusivity, and equitable economics reinforce each other, turning AI from a hype‑driven shortcut into a genuine catalyst for affordable, accessible medicines.